Bristol-Myers Squibb’s KRAS inhibitor Krazati has been approved for a second indication, colorectal cancer (CRC), which could inject some much-needed sales growth into the product.
The first patient has received a personalised colorectal cancer vaccine, produced by BioNTech, as part of NHS England and Genomics England’s Cancer Vaccine Launch Pad (CVL
An artificial intelligence-powered computer-aided detection (CAD) system developed by Israeli medtech company Magentiq-Eye has been shown to improve detection rates for ad
The combination of Bristol-Myers Squibb’s Opdivo and Yervoy cancer immunotherapies is on track for approval as a first-line therapy for patients with a particular form of
Germany’s Merck KGaA is paying $45 million upfront for rights to a potentially first-in-class drug for colorectal cancer (CRC) being developed by New York biotech Inspirna
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh